Combined systemic and intratumoral administration of human papillomavirus vaccine to treat multiple cutaneous basaloid squamous cell carcinomas

Anna J. Nichols, Adrianna Gonzalez, Emily S. Clark, Wasif Khan, Alyx C. Rosen, Wellington Guzman, Harold Rabinovitz, Evangelos V Badiavas, Robert Kirsner, Tim Ioannides

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

IMPORTANCE Squamous cell carcinoma (SCC) is the second most common form of skin cancer, and its incidence is increasing. When surgical management is not an option, finding a safe and efficacious treatment is a challenge. Mounting evidence suggests that the human papillomavirus (HPV) is involved in the pathogenesis of some SCCs. OBJECTIVE To assess whether the 9-valent HPV vaccine could be an effective treatment strategy for cutaneous SCC. DESIGN, SETTING, AND PARTICIPANTS A woman in her 90s with multiple, inoperable cutaneous basaloid SCCs was successfully treated at a university-based outpatient dermatology clinic with a combination of systemic and intratumoral delivery of the 9-valent HPV vaccine from March 17, 2016, through February 27, 2017, and then followed up through May 21, 2018. MAIN OUTCOMES AND MEASURES Reduction in tumor size and number after a combination of systemic and intratumoral administration of the HPV vaccine. RESULTS All tumors resolved 11 months after the first intratumoral injection of the vaccine. The patient remained free of tumors at the end of follow-up. CONCLUSIONS AND RELEVANCE This is the first report, to our knowledge, of complete regression of a cutaneous malignant tumor after combined systemic and direct intratumoral injection of the 9-valent HPV vaccine. This report suggests that the HPV vaccine may have therapeutic utility for SCCs in patients who are poor surgical candidates, have multiple lesions, or defer surgery.

Original languageEnglish (US)
Pages (from-to)927-930
Number of pages4
JournalJAMA Dermatology
Volume154
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Papillomavirus Vaccines
Squamous Cell Carcinoma
Skin
Neoplasms
Injections
Skin Neoplasms
Dermatology
Ambulatory Care Facilities
Therapeutics
Vaccines
Outcome Assessment (Health Care)
Incidence

ASJC Scopus subject areas

  • Dermatology

Cite this

Combined systemic and intratumoral administration of human papillomavirus vaccine to treat multiple cutaneous basaloid squamous cell carcinomas. / Nichols, Anna J.; Gonzalez, Adrianna; Clark, Emily S.; Khan, Wasif; Rosen, Alyx C.; Guzman, Wellington; Rabinovitz, Harold; Badiavas, Evangelos V; Kirsner, Robert; Ioannides, Tim.

In: JAMA Dermatology, Vol. 154, No. 8, 01.08.2018, p. 927-930.

Research output: Contribution to journalArticle

Nichols, Anna J. ; Gonzalez, Adrianna ; Clark, Emily S. ; Khan, Wasif ; Rosen, Alyx C. ; Guzman, Wellington ; Rabinovitz, Harold ; Badiavas, Evangelos V ; Kirsner, Robert ; Ioannides, Tim. / Combined systemic and intratumoral administration of human papillomavirus vaccine to treat multiple cutaneous basaloid squamous cell carcinomas. In: JAMA Dermatology. 2018 ; Vol. 154, No. 8. pp. 927-930.
@article{f7313acd789447c59a45bb21aee85159,
title = "Combined systemic and intratumoral administration of human papillomavirus vaccine to treat multiple cutaneous basaloid squamous cell carcinomas",
abstract = "IMPORTANCE Squamous cell carcinoma (SCC) is the second most common form of skin cancer, and its incidence is increasing. When surgical management is not an option, finding a safe and efficacious treatment is a challenge. Mounting evidence suggests that the human papillomavirus (HPV) is involved in the pathogenesis of some SCCs. OBJECTIVE To assess whether the 9-valent HPV vaccine could be an effective treatment strategy for cutaneous SCC. DESIGN, SETTING, AND PARTICIPANTS A woman in her 90s with multiple, inoperable cutaneous basaloid SCCs was successfully treated at a university-based outpatient dermatology clinic with a combination of systemic and intratumoral delivery of the 9-valent HPV vaccine from March 17, 2016, through February 27, 2017, and then followed up through May 21, 2018. MAIN OUTCOMES AND MEASURES Reduction in tumor size and number after a combination of systemic and intratumoral administration of the HPV vaccine. RESULTS All tumors resolved 11 months after the first intratumoral injection of the vaccine. The patient remained free of tumors at the end of follow-up. CONCLUSIONS AND RELEVANCE This is the first report, to our knowledge, of complete regression of a cutaneous malignant tumor after combined systemic and direct intratumoral injection of the 9-valent HPV vaccine. This report suggests that the HPV vaccine may have therapeutic utility for SCCs in patients who are poor surgical candidates, have multiple lesions, or defer surgery.",
author = "Nichols, {Anna J.} and Adrianna Gonzalez and Clark, {Emily S.} and Wasif Khan and Rosen, {Alyx C.} and Wellington Guzman and Harold Rabinovitz and Badiavas, {Evangelos V} and Robert Kirsner and Tim Ioannides",
year = "2018",
month = "8",
day = "1",
doi = "10.1001/jamadermatol.2018.1748",
language = "English (US)",
volume = "154",
pages = "927--930",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Combined systemic and intratumoral administration of human papillomavirus vaccine to treat multiple cutaneous basaloid squamous cell carcinomas

AU - Nichols, Anna J.

AU - Gonzalez, Adrianna

AU - Clark, Emily S.

AU - Khan, Wasif

AU - Rosen, Alyx C.

AU - Guzman, Wellington

AU - Rabinovitz, Harold

AU - Badiavas, Evangelos V

AU - Kirsner, Robert

AU - Ioannides, Tim

PY - 2018/8/1

Y1 - 2018/8/1

N2 - IMPORTANCE Squamous cell carcinoma (SCC) is the second most common form of skin cancer, and its incidence is increasing. When surgical management is not an option, finding a safe and efficacious treatment is a challenge. Mounting evidence suggests that the human papillomavirus (HPV) is involved in the pathogenesis of some SCCs. OBJECTIVE To assess whether the 9-valent HPV vaccine could be an effective treatment strategy for cutaneous SCC. DESIGN, SETTING, AND PARTICIPANTS A woman in her 90s with multiple, inoperable cutaneous basaloid SCCs was successfully treated at a university-based outpatient dermatology clinic with a combination of systemic and intratumoral delivery of the 9-valent HPV vaccine from March 17, 2016, through February 27, 2017, and then followed up through May 21, 2018. MAIN OUTCOMES AND MEASURES Reduction in tumor size and number after a combination of systemic and intratumoral administration of the HPV vaccine. RESULTS All tumors resolved 11 months after the first intratumoral injection of the vaccine. The patient remained free of tumors at the end of follow-up. CONCLUSIONS AND RELEVANCE This is the first report, to our knowledge, of complete regression of a cutaneous malignant tumor after combined systemic and direct intratumoral injection of the 9-valent HPV vaccine. This report suggests that the HPV vaccine may have therapeutic utility for SCCs in patients who are poor surgical candidates, have multiple lesions, or defer surgery.

AB - IMPORTANCE Squamous cell carcinoma (SCC) is the second most common form of skin cancer, and its incidence is increasing. When surgical management is not an option, finding a safe and efficacious treatment is a challenge. Mounting evidence suggests that the human papillomavirus (HPV) is involved in the pathogenesis of some SCCs. OBJECTIVE To assess whether the 9-valent HPV vaccine could be an effective treatment strategy for cutaneous SCC. DESIGN, SETTING, AND PARTICIPANTS A woman in her 90s with multiple, inoperable cutaneous basaloid SCCs was successfully treated at a university-based outpatient dermatology clinic with a combination of systemic and intratumoral delivery of the 9-valent HPV vaccine from March 17, 2016, through February 27, 2017, and then followed up through May 21, 2018. MAIN OUTCOMES AND MEASURES Reduction in tumor size and number after a combination of systemic and intratumoral administration of the HPV vaccine. RESULTS All tumors resolved 11 months after the first intratumoral injection of the vaccine. The patient remained free of tumors at the end of follow-up. CONCLUSIONS AND RELEVANCE This is the first report, to our knowledge, of complete regression of a cutaneous malignant tumor after combined systemic and direct intratumoral injection of the 9-valent HPV vaccine. This report suggests that the HPV vaccine may have therapeutic utility for SCCs in patients who are poor surgical candidates, have multiple lesions, or defer surgery.

UR - http://www.scopus.com/inward/record.url?scp=85051273314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051273314&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2018.1748

DO - 10.1001/jamadermatol.2018.1748

M3 - Article

C2 - 29971321

AN - SCOPUS:85051273314

VL - 154

SP - 927

EP - 930

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 8

ER -